SCHEMBL2354671

SCHEMBL2354671

Cc1c(C(=O)O)ccc2cc(Br)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 1/20 0.47
EPRS1 P07814 2/20 0.46
NR4A1 P22736 2/20 0.45
MYC P01106 1/20 0.45
KDM4E B2RXH2 2/20 0.45
GLA P06280 2/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
PPARG P37231 1/20 0.45
RECQL P46063 1/20 0.45
MCL1 Q07820 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
GRIN1 Q05586 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4137339 0.81 CA12 (0.50) MEN1KMT2AMYCALDH1A1POLB
SCHEMBL2749203 0.81 PTPN1 (0.59) MEN1KMT2ANPC1MYCKDM4E
SCHEMBL15528059 0.81 RXFP1 (0.53) RXFP1MEN1KMT2ANPC1NR4A1
SCHEMBL26205125 0.79 RXFP1 (0.55) RXFP1MEN1KMT2ANPC1NR4A1
SCHEMBL28852457 0.79 RXFP1 (0.48) RXFP1MEN1KMT2ANPC1EPRS1
SCHEMBL23909563 0.77 PTPN1 (0.46) MYCKDM4EALDH1A1MAPTHPGD
SCHEMBL10015552 0.77 CYP1A2 (0.50) MEN1KMT2AMYCKDM4EALDH1A1
SCHEMBL4751251 0.76 ALDH1A1 (0.48) RXFP1MEN1KMT2ANPC1NR4A1
SCHEMBL821838 0.75 PTPN1 (0.66) RXFP1MEN1KMT2ANR4A1KDM4E
SCHEMBL2466414 0.75 RXFP1 (0.46) RXFP1MEN1KMT2ANPC1EPRS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007125542-A2 A PROCESS FOR PREPARATION OF ADAPALENE USV LIMITED (IN) 2007-11-08 WO claimed
WO-2023061999-A1 PROCESS FOR PREPARING A PHENOLIC HYDROCARBON STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2023-04-20 WO disclosed
EP-4166531-A1 PROCESS FOR PREPARING A PHENOLIC HYDROCARBON Studiengesellschaft Kohle mbH (DE) 2023-04-19 EP disclosed
EP-1853261-B1 SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHASES UNIV SAARLAND (DE) 2017-01-11 EP disclosed
US-9271963-B2 Selective inhibitors of human corticosteroid synthases UNIVERSITAT DES SAARLANDES (DE) 2016-03-01 US disclosed
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-8071598-B2 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-12-06 US disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
EP-2350119-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE Merlion Pharmaceuticals Pte Ltd. (SG) 2011-08-03 EP disclosed
WO-2007125542-A2 A PROCESS FOR PREPARATION OF ADAPALENE USV LIMITED (IN) 2007-11-08 WO disclosed
WO-2007125542-A2 A PROCESS FOR PREPARATION OF ADAPALENE USV LIMITED (IN) 2007-11-08 WO disclosed
WO-2007090886-A1 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-08-16 WO disclosed
WO-2006092430-A1 SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHASES Universität des Saarlandes (DE) 2006-09-08 WO disclosed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R RXFP1 2113/4885MEN1 3139/4885KMT2A 3944/4885
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 RXFP1 579/4885MEN1 2415/4885KMT2A 3759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.